Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CEBP Focus Archive
    • Meeting Abstracts
    • Progress and Priorities
    • Collections
      • COVID-19 & Cancer Resource Center
      • Disparities Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Informing Public Health Policy
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Epidemiology, Biomarkers & Prevention
Cancer Epidemiology, Biomarkers & Prevention
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CEBP Focus Archive
    • Meeting Abstracts
    • Progress and Priorities
    • Collections
      • COVID-19 & Cancer Resource Center
      • Disparities Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Informing Public Health Policy
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Null Results in Brief

A Prospective Study of Aspirin Use and Prostate Cancer Risk by TMPRSS2:ERG Status

Konrad H. Stopsack, Amparo G. Gonzalez-Feliciano, Samuel F. Peisch, Mary K. Downer, Riley A. Gage, Stephen Finn, Rosina T. Lis, Rebecca E. Graff, Andreas Pettersson, Claire H. Pernar, Massimo Loda, Philip W. Kantoff, Thomas U. Ahearn and Lorelei A. Mucci; on behalf of the Transdisciplinary Prostate Cancer Partnership (ToPCaP)
Konrad H. Stopsack
1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
2Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Konrad H. Stopsack
  • For correspondence: stopsack@mskcc.org
Amparo G. Gonzalez-Feliciano
2Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Samuel F. Peisch
2Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mary K. Downer
2Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
3Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Riley A. Gage
2Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephen Finn
4Department of Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
5Department of Pathology, Trinity College Dublin, Dublin, Ireland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Stephen Finn
Rosina T. Lis
6Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rebecca E. Graff
2Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
7Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Rebecca E. Graff
Andreas Pettersson
2Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
8Department of Medicine, Clinical Epidemiology Unit, Solna, Karolinska Institutet, Stockholm, Sweden.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Claire H. Pernar
2Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Massimo Loda
4Department of Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Philip W. Kantoff
1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas U. Ahearn
9National Cancer Institute, Division of Cancer Epidemiology and Genetics, Epidemiology and Biostatistics Program, Bethesda, Maryland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lorelei A. Mucci
2Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
3Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1055-9965.EPI-18-0510 Published October 2018
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background: In a case–control study, aspirin use was associated with a lower risk of a common prostate cancer molecular subtype, the TMPRSS2:ERG gene fusion. We sought to validate this finding in a prospective cohort.

Methods: In the Health Professionals Follow-up Study, 49,395 men reported on aspirin use on biennial questionnaires and were followed for prostate cancer incidence over 23 years. TMPRSS2:ERG status was assessed by IHC for presence of ERG on archival tumor specimens for 912 patients with prostate cancer, of whom 48% were ERG-positive.

Results: In multivariable models, we found no association between regular use of aspirin and risk of ERG-positive prostate cancer (HR, 1.02; 95% confidence interval, 0.85–1.23), nor any association with duration or frequency of aspirin use. In restricting to cases with either high Gleason grade or advanced stage disease, there remained no association with aspirin use.

Conclusions: Data from this prospective study with repeated assessments of aspirin use do not support the hypothesis that aspirin use is associated with a lower risk of ERG-positive prostate cancer.

Impact: Aspirin use is unlikely to lower the risk of this common molecular subtype of prostate cancer. However, there is emerging data supporting the role of other lifestyle and genetic factors underlying the development of the TMPRSS2:ERG fusion. Cancer Epidemiol Biomarkers Prev; 27(10); 1231–3. ©2018 AACR.

Introduction

The TMPRSS2:ERG gene fusion is the most common somatic event in primary prostate cancer, with an estimated 100,000 U.S. patients diagnosed with TMPRSS2:ERG-positive cancer annually. Our group and others have reported on associations between lifestyle and inherited genetic factors specifically associated with TMPRSS2:ERG-defined disease (1–4). In a retrospective case–control study, current aspirin use was associated with a lower risk of TMPRSS2:ERG-positive cancer [OR, 0.63; 95% confidence interval (CI), 0.43–0.93], whereas there was no association with cancers that lacked TMPRSS2:ERG (OR, 0.99; 95% CI, 0.69–1.42; ref. 5). The authors speculated that aspirin may protect against TMPRSS2:ERG-positive cancer through reduction in cellular stress, inflammation, and DNA damage. We sought to validate this association in a prospective cohort of men with longitudinal measures of aspirin use and 23 years of follow-up for prostate cancer incidence.

Materials and Methods

This study was nested in the Health Professionals Follow-up Study (HPFS), a cohort of 51,529 male health professionals age 40 to 75 years at baseline in 1986 (6). For this study, we excluded men with cancer diagnoses other than nonmelanoma skin cancer before 1986 (n = 2,076), missing age or diagnosis date (n = 42), and implausible diagnosis or death dates (n = 16). Participants responded to biennial questionnaires on lifestyle, diet (every 4 years), diagnoses, and medication use. Biennial follow-up rates exceeded 93%. Patients with incident prostate cancer were followed with specific questionnaires. Clinical data were abstracted from medical records and pathology reports.

On biennial questionnaires, participants reported current regular aspirin use (with example brand names provided). If participants did not return a specific questionnaire, their prior response was carried forward. Starting in 1992, men reported categories of frequency of use, and we defined regular use as ≥2 days/week.

We characterized TMPRSS2:ERG status on tumor tissue microarrays from men who underwent radical prostatectomy (n = 912) using a genomically validated immunohistochemistry method for the ERG protein (7). A case was scored ERG-positive if at least one core had positive ERG staining within cancer cells.

Cox proportional hazards models, adjusted for predefined covariates, were used to estimate HRs and two-sided 95% CIs for total, advanced (stage, ≥T3b/N1, or M1 at any time), and high-grade (Gleason grade, ≥4 + 3) cancers, each according to ERG status.

Results

Among 49,395 men, 14,547 (29.4%) were current aspirin users at baseline in 1986. In 2008, 47.2% and 36.3% of the remaining 28,355 participants were current and past aspirin users, respectively. A total of 6,189 participants (12.5%) were diagnosed with incident prostate cancer (Table 1). From 2,332 patients treated with prostatectomy, ERG status was available for 912 tumors.

View this table:
  • View inline
  • View popup
Table 1.

Characteristics of participants of the HPFS by aspirin use at baseline, standardized to the age distribution of the study population

There was no statistically significant association between current regular aspirin use and the risk of ERG-positive (HR, 1.02; 95% CI, 0.85–1.23) or ERG-negative prostate cancer (HR, 1.09; 95% CI, 0.91–1.30; Pheterogeneity = 0.69 by ERG status), nor for total prostate cancer including all cases (HR, 1.05; 95% CI, 0.99–1.10) in fully adjusted models. Dose–response analyses according to cumulative duration or frequency of aspirin use were null (Table 2). Results for ERG-positive cancer were also null for age-adjusted models for advanced and high-grade cancer.

View this table:
  • View inline
  • View popup
Table 2.

ERG-positive and ERG-negative incident prostate cancer by aspirin use (fully adjusted modela)

Discussion

In this prospective study with updated information on aspirin, we found no association between regular aspirin use and risk of ERG-positive prostate cancer. Similarly, we found no association between duration or frequency of aspirin use and ERG-positive disease, including for clinically significant high-risk cancers. Our findings are in contrast with those of Wright and colleagues’ (5), who reported a strong inverse association in their case–control study, which included 346 cases (49% ERG-positive) and 942 controls.

Differences in results may partly be due to differences in study design. First, our study was nested in a prospective cohort, whereas the prior study collected data from cases after diagnosis and used random digit dialing to select controls free from prostate cancer. Second, genetic and environmental factors are associated with ERG status (1–4) and could lead to confounding if not controlled for (5). In our study population, however, adjusted and unadjusted estimates were nearly identical. Third, misclassification of aspirin exposure is expected to be nondifferential in HPFS, where medical professionals repeatedly reported on medication use before cancer diagnosis. Recall bias in the prior study cannot account for differences in risk according to ERG status, which was unknown to participants. It is unlikely that ERG assessment via IHC or FISH would have biased either study's result (7). Finally, differences in results may be due to chance. Our study had >99% power to detect an HR of 0.63, corresponding to the previously reported effect size (5).

In summary, our data do not support the hypothesis that aspirin use lowers the risk of TMPRSS2:ERG-positive prostate cancer. Emerging data suggest other modifiable etiologic and prognostic factors for this common molecular subtype (1–4, 8).

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Authors' Contributions

Conception and design: M.K. Downer, A. Pettersson, L.A. Mucci

Development of methodology: M.K. Downer, S. Finn, R.E. Graff

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): S. Finn, R.T. Lis, L.A. Mucci

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): K.H. Stopsack, A.G. Gonzalez-Feliciano, M.K. Downer, A. Pettersson, M. Loda, P.W. Kantoff, T.U. Ahearn, L.A. Mucci

Writing, review, and/or revision of the manuscript: K.H. Stopsack, A.G. Gonzalez-Feliciano, S.F. Peisch, M.K. Downer, R.A. Gage, S. Finn, R.T. Lis, R.E. Graff, A. Pettersson, C.H. Pernar, M. Loda, P.W. Kantoff, T.U. Ahearn, L.A. Mucci

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): S.F. Peisch, M.K. Downer, R.T. Lis

Study supervision: L.A. Mucci

Acknowledgments

We would like to thank the participants and staff of the Health Professionals Follow-up Study for their valuable contributions as well as the following state cancer registries for their help: AL, AZ, AR, CA, CO, CT, DE, FL, GA, ID, IL, IN, IA, KY, LA, ME, MD, MA, MI, NE, NH, NJ, NY, NC, ND, OH, OK, OR, PA, RI, SC, TN, TX, VA, WA, WY. The authors assume full responsibility for analyses and interpretation of these data. In particular, we would like to recognize the contributions of Liza Gazeeva, Siobhan Saint-Surin, Robert Sheahan, and Betsy Frost-Hawes. The Health Professionals Follow-up Study was supported by NIH grant U01 CA167552. This research was funded in part by the Dana-Farber/Harvard Cancer Center Specialized Programs of Research Excellence program in Prostate Cancer (5P50 CA090381), the NCI (R01CA136578 to L.A. Mucci; T32CA09001 to M.K. Downer and C.H. Pernar; and R25CA112355 to R.E. Graff), and the NIH/NCI Cancer Center Support Grants P30 CA008748 and P30 CA06516. K.H. Stopsack, S. Finn, and L.A. Mucci are Prostate Cancer Foundation Young Investigators.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

  • Received May 10, 2018.
  • Revision received May 30, 2018.
  • Accepted July 30, 2018.
  • Published first August 14, 2018.
  • ©2018 American Association for Cancer Research.

References

  1. 1.↵
    1. Graff RE,
    2. Meisner A,
    3. Ahearn TU,
    4. Fiorentino M,
    5. Loda M,
    6. Giovannucci EL,
    7. et al.
    Pre-diagnostic circulating sex hormone levels and risk of prostate cancer by ERG tumour protein expression. Br J Cancer 2016;114:939–44.
    OpenUrl
  2. 2.↵
    1. Egbers L,
    2. Luedeke M,
    3. Rinckleb A,
    4. Kolb S,
    5. Wright JL,
    6. Maier C,
    7. et al.
    Obesity and prostate cancer risk according to tumor TMPRSS2:ERG gene fusion status. Am J Epidemiol 2015;181:706–13.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Graff RE,
    2. Pettersson A,
    3. Lis RT,
    4. Ahearn TU,
    5. Markt SC,
    6. Wilson KM,
    7. et al.
    Dietary lycopene intake and risk of prostate cancer defined by ERG protein expression. Am J Clin Nutr 2016;103:851–60.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Penney KL,
    2. Pettersson A,
    3. Shui IM,
    4. Graff RE,
    5. Kraft P,
    6. Lis RT,
    7. et al.
    Association of prostate cancer risk variants with TMPRSS2:ERG status: evidence for distinct molecular subtypes. Cancer Epidemiol Biomarkers Prev 2016;25:745–9.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Wright JL,
    2. Chery L,
    3. Holt S,
    4. Lin DW,
    5. Luedeke M,
    6. Rinckleb AE,
    7. et al.
    Aspirin and NSAID use in association with molecular subtypes of prostate cancer defined by TMPRSS2:ERG fusion status. Prostate Cancer Prostatic Dis 2016;19:53–6.
    OpenUrl
  6. 6.↵
    1. Giovannucci E,
    2. Liu Y,
    3. Platz EA,
    4. Stampfer MJ,
    5. Willett WC
    . Risk factors for prostate cancer incidence and progression in the health professionals follow-up study. Int J Cancer 2007;121:1571–8.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Pettersson A,
    2. Graff RE,
    3. Bauer SR,
    4. Pitt MJ,
    5. Lis RT,
    6. Stack EC,
    7. et al.
    The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis. Cancer Epidemiol Biomarkers Prev 2012;21:1497–509.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Pettersson A,
    2. Lis RT,
    3. Meisner A,
    4. Flavin R,
    5. Stack EC,
    6. Fiorentino M,
    7. et al.
    Modification of the association between obesity and lethal prostate cancer by TMPRSS2:ERG. J Natl Cancer Inst 2013;105:1881–90.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top
Cancer Epidemiology Biomarkers & Prevention: 27 (10)
October 2018
Volume 27, Issue 10
  • Table of Contents
  • Table of Contents (PDF)
  • Editorial Board (PDF)

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Epidemiology, Biomarkers & Prevention article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
A Prospective Study of Aspirin Use and Prostate Cancer Risk by TMPRSS2:ERG Status
(Your Name) has forwarded a page to you from Cancer Epidemiology, Biomarkers & Prevention
(Your Name) thought you would be interested in this article in Cancer Epidemiology, Biomarkers & Prevention.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
A Prospective Study of Aspirin Use and Prostate Cancer Risk by TMPRSS2:ERG Status
Konrad H. Stopsack, Amparo G. Gonzalez-Feliciano, Samuel F. Peisch, Mary K. Downer, Riley A. Gage, Stephen Finn, Rosina T. Lis, Rebecca E. Graff, Andreas Pettersson, Claire H. Pernar, Massimo Loda, Philip W. Kantoff, Thomas U. Ahearn and Lorelei A. Mucci on behalf of the Transdisciplinary Prostate Cancer Partnership (ToPCaP)
Cancer Epidemiol Biomarkers Prev October 1 2018 (27) (10) 1231-1233; DOI: 10.1158/1055-9965.EPI-18-0510

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
A Prospective Study of Aspirin Use and Prostate Cancer Risk by TMPRSS2:ERG Status
Konrad H. Stopsack, Amparo G. Gonzalez-Feliciano, Samuel F. Peisch, Mary K. Downer, Riley A. Gage, Stephen Finn, Rosina T. Lis, Rebecca E. Graff, Andreas Pettersson, Claire H. Pernar, Massimo Loda, Philip W. Kantoff, Thomas U. Ahearn and Lorelei A. Mucci on behalf of the Transdisciplinary Prostate Cancer Partnership (ToPCaP)
Cancer Epidemiol Biomarkers Prev October 1 2018 (27) (10) 1231-1233; DOI: 10.1158/1055-9965.EPI-18-0510
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosure of Potential Conflicts of Interest
    • Authors' Contributions
    • Acknowledgments
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Associations of ACEi and ARB with CRC risk
  • PDE5 Inhibitor Use and Precursors of Colorectal Cancer
  • Association Between Serum Iron Biomarkers and Breast Cancer
Show more Null Results in Brief
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Epidemiology, Biomarkers & Prevention

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Epidemiology, Biomarkers & Prevention
eISSN: 1538-7755
ISSN: 1055-9965

Advertisement